Immune Cell-Derived Exosomes: A Cell-Free Cutting-Edge Tumor Immunotherapy

ACS Appl Bio Mater. 2024 Nov 18;7(11):7076-7087. doi: 10.1021/acsabm.4c00660. Epub 2024 Nov 4.

Abstract

Extracellular vesicles (EVs) are cellular communication molecules and are classified into three major subpopulations, such as microvesicles, apoptotic bodies, and exosomes. Among these, exosomes-based cancer research is a cutting-edge investigation approach to cancer understanding. During cancer progression , tumor-derived exosomes can reprogram the cellular system and promote cancer. Circulating exosomes in the body fluids such as blood, plasma, serum, saliva, CSF, sweat, and tears play a key role in identifying diagnostic and prognostic cancer biomarkers. Diverse therapeutic sources of exosomes including stem cells, plants, and immune cells, etc. exhibit significant cancer-healing properties. Although cancer-targeting immunotherapy is an effective strategy, it has limitations such as toxicity, and high costs. In comparison, immune cell-derived exosomes-based immunotherapy is a cell-free approach for cancer treatment and has advantages like less toxicity, biocompatibility, reduced immunogenicity, and efficient, target-specific cancer therapeutic development. This review highlights the therapeutic signature of immune cell-derived exosomes for cancer treatment.

Keywords: Cancer; Exosomes; Extracellular vesicles; Immunotherapy; Metastasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Biocompatible Materials / chemistry
  • Biocompatible Materials / pharmacology
  • Exosomes* / chemistry
  • Exosomes* / immunology
  • Exosomes* / metabolism
  • Humans
  • Immunotherapy*
  • Neoplasms* / immunology
  • Neoplasms* / therapy

Substances

  • Biocompatible Materials